Though the company’s logo is prominently displayed in the final shots of the ad, the campaign is an unbranded one: It doesn’t specifically mention Prevnar 20, and the VaxAssist website gives ...

You’ve come to the right place. But before jumping into the hints and solutions for the Thursday, March 20 puzzle, let’s go over the basics of Wordle. Wordle is a word puzzle that gives ...

At All Doses Evaluated, VAX-24 Was Well-Tolerated and Demonstrated a Safety and Tolerability Profile Similar to Prevnar 20 ® (PCV20) -- -- At All Doses Evaluated, VAX-24 Elicited Substantial Immune ...

Vaxcyte (PCVX) shared topline results from its Phase 2 dose-finding study evaluating the safety, tolerability and immunogenicity of VAX-24, ...

Spanish soccer club Leganes has joined the fight against testicular cancer by planning to wear attention-grabbing shorts for its upcoming game against Barcelona.

It covers 15 different pneumococcal serotypes – two more than Pfizer's current Prevnar 13 shot – and has been approved for use in patients aged 18 or over. Pfizer's updated 20-valent vaccine ...

Pfizer PFE is a key player in the PCV vaccine space. PFE markets Prevnar 20, which is approved for the prevention of IPD caused by 20 serotypes in individuals aged six weeks and older. PFE also ...

The study is evaluating the effectiveness of VAX-24 compared to Pfizer's (NYSE:PFE) Prevnar 20 vaccine. One reason for the dramatic decline is likely the impending departure of Peter Marks ...

Germany 20 Year Government Bond-0.1360 2.9680% ...

Pfizer is fighting back with the approval of its new Prevnar 20 shot last month, covering 20 serotypes, but ASP3772 is attempting to go even further with coverage of 24 serotypes thanks to ...

candidate designed to prevent invasive pneumococcal disease (IPD), compared to Prevnar 20 ® (PCV20) in healthy infants. Based on these findings, the Company has selected the VAX-24 Mid dose as ...

VAX-24 Mid dose met Phase 2 non-inferiority criteria for 20 of 24 serotypes and showed strong immune responses across all doses. Full post-dose 4 booster data is expected by late 2025, with a ...